No Detail Found!

Recurrent rectal carcinoma treated with high dose rate intraluminal brachytherapy.

Author(s)
Naseem Begum Department of Radiotherapy, Institute of Radiotherapy and Nuclear Medicine (IRNUM), Peshawar, Pakistan
H. Asghar Department of Radiotherapy, Institute of Radiotherapy and Nuclear Medicine (IRNUM), Peshawar, Pakistan
N. Asghar Department of Radiotherapy, Institute of Radiotherapy and Nuclear Medicine (IRNUM), Peshawar, Pakistan
N. Shahida Department of Radiotherapy, Institute of Radiotherapy and Nuclear Medicine (IRNUM), Peshawar, Pakistan
G. A. Jawad Department of Radiotherapy, Institute of Radiotherapy and Nuclear Medicine (IRNUM), Peshawar, Pakistan
K. M. Sher Department of Nuclear Medicine, Institute of Radiotherapy and Nuclear Medicine, Peshawar, Pakistan
K Ayub Department of Nuclear Medicine, Institute of Radiotherapy and Nuclear Medicine, Peshawar, Pakistan
Abstract
A 65 year old man with recurrent rectal cancer was treated with remote after loading High Dose Rate Intraluminal Brachytherapy (HDRILB.). After eight weeks of HDRILB there was complete regression of the tumor. Bleeding per rectum and pain in the perineum were greatly improved. He died of myocardial infarction after 41 months of treatment with HDRILB. The treated lesions were incomplete remission at the time of death. The procedure was well tolerated. The only treatment-associated toxicity was grade 2 procitis, which was treated conservatively. HDRILB can be used as one of the treatment options in patients with recurrent rectal cancers who have undergone previous abdominal surgery and external beam irradiation, as exhibited in our limited experience.
Publication Details
Page(s) 528-529
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 13, Issue: 9, Year: 2003

Request the full text from PASTIC

0

Citations

0

Downloads

57

Views